Jefferies Adjusts Viatris Price Target
Investment firm Jefferies has raised its price target for Viatris Inc. from $20.00 to $22.00.
Stocks · News reference
Viatris Inc. has officially commenced a cash tender offer to acquire all outstanding shares of Pacira BioSciences for $36.50 per share.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Investment firm Jefferies has raised its price target for Viatris Inc. from $20.00 to $22.00.
Viatris reported Q3 2026 revenue of $3.75 billion, down 0.3% year-over-year and slightly missing consensus estimates by 0.76%. However, the company delivered a strong EPS beat of 10.94%, reporting $0.71 versus the expected $0.64. Regional performance was mixed, with Greater China showing strong growth of 14.2%, while Emerging Markets Generics declined sharply by 36.5%. The stock has outperformed the broader market with a 9.9% return over the past month and currently holds a Zacks Rank #3 (Hold) rating.
Viatris (NASDAQ:VTRS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
Filed: 2026-11-05 AccNo: 0001792044-26-000053 Size: 872 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Viatris announced its third-quarter 2026 financial results, reporting a net loss of $325.3 million and an EPS of -$0.28, while simultaneously raising its full-year 2026 guidance across key metrics.
Viatris Inc. has announced a quarterly cash dividend of $0.12 per share for its shareholders.